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Purpose: 
The objective of this study is to characterize the prophylactic antiemetic 
regimens used in pediatric hematology/oncology patients receiving 
moderately and highly emetogenic chemotherapy (MEC/HEC) and to describe 
the modifications to their antiemetic regimens with subsequent courses of 
chemotherapy. 
Background: 
 •  Recommendations for prophylactic antiemetics differ between adults and 
pediatrics
	 	 	 -	 	American	Society	of	Clinical	Oncology	(ASCO)	recommends	a	serotonin	
(5-HT3)	antagonist	plus	a	corticosteroid	for	pediatric	patients	receiving	
MEC	or	HEC1
	 	 	 -	 	Patients	with	a	contraindication	to	corticosteroids	should	not	use	a	5-
HT3	antagonist	alone	due	to	poor	CINV	control2
	 	 	 -	 	Pediatric	Oncology	Group	of	Ontario	(POGO)	suggests	nabilone	
or	chlorpromazine	with	a	5-HT3	antagonist	in	patients	with	a	
contraindication	to	corticosteroids2
	 	 	 	 	 	 •		These	agents	are	commonly	reserved	for	patients	with	
breakthrough	CINV	due	to	undesirable	side	effects2-4		
	 	 	 	 	 	 •		Recommendation	supports	the	need	to	add	an	agent	with	a	
different	mechanism	of	action	to	replace	the	corticosteroid	within	
the	antiemetic	regimen2-4
•  Pediatric-specific recommendations are lacking for incorporation of newer 
agents into prophylactic antiemetic regimens
• Breakthrough emesis is a significant problem
	 	 	 -	 	More	than	90%	of	patients	receiving	HEC	will	have	emesis	and	
prophylactic	antiemetics	will	only	reduce	vomiting	to	about	30%5
	 	 	 -	 	Prophylactic	regimens	should	be	modified	and	tailored	to	the	individual	
patient	to	prevent	CINV	with	subsequent	chemotherapy	cycles
	 	 	 -	 	No	studies	have	shown	one	agent	or	strategy	to	be	superior
Study Design: 
 •  Retrospective medical record review
 •  Inclusion criteria:
	 	 	 -	 	Patients	less	than	18	years	of	age	at	time	of	first	MEC	or	HEC	course	
between	July	1,	2008	to	June	30,	2013
	 	 	 -	 	Receipt	of	first	MEC	or	HEC	course	for	an	oncologic	diagnosis	during	
an	inpatient	admission	to	a	pediatric	service




•  Exclusion criteria:
	 	 	 -	 	Patients	18	years	of	age	and	older	at	time	of	first	MEC	or	HEC	course
	 	 	 -	 	Outpatient	chemotherapy	administrations
	 	 	 -	 	Patients	with	documented	nausea	and/or	vomiting	related	to	cause	
other	than	chemotherapy
	 	 	 -	 	Patients	who	received	radiation	therapy	prior	to	initiation	of	
chemotherapy	
•  The primary outcomes of this study will be to describe the combinations 
of antiemetic regimens that patients received following receipt of MEC or 
HEC and to report the percentage of patients whose prophylactic antiemetic 
regimens were modified for subsequent courses of chemotherapy
Methods: 
 •  Pediatric hematology/oncology admission records will be used to generate a 
list of patients
 •  Emetogenicity will be classified as reported by the NCCN guidelines5 
 • Patient data to be collected will include:
	 	 	 -	 	Age,	gender,	body	weight,	body	surface	area
	 	 	 -	 	Diagnosis	
	 	 	 -	 	Chemotherapy	regimen	(protocol,	drug,	dose,	route),	emetogenicity	of	
regimen
	 	 	 -	 	Antiemetic	regimens	(initial,	modified	and	breakthrough;	drug,	dose,	
route,	frequency,	days	of	administration,	number	of	doses)
	 	 	 -	 	Emetic	events
	 	 	 -	 	Antiemetic	adverse	drug	reaction	history
•  Following data collection, the percentages of pediatric oncology patients 
receiving MEC or HEC who experience breakthrough nausea and/or vomiting 
will be calculated.  Of those patients, the percentage who had their antiemetic 
regimen modified for subsequent courses of chemotherapy will be calculated.	
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